Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2421411 | 0.90 | MAPK9 (0.53) | MAPTMAPK9MAPK10MEN1KMT2A | |
| SCHEMBL3479967 | 0.87 | MAPK9 (0.51) | MAPTMAPK9MAPK10MEN1KMT2A | |
| SCHEMBL2424858 | 0.86 | MAPK9 (0.61) | MAPTMAPK9MAPK10MEN1KMT2A | |
| SCHEMBL2421105 | 0.85 | MAPK9 (0.53) | MAPTMAPK9MAPK10MEN1KMT2A | |
| SCHEMBL2423054 | 0.85 | MAPK9 (0.59) | MAPTMAPK9MAPK10MEN1KMT2A | |
| SCHEMBL2424204 | 0.85 | MAPK9 (0.51) | MAPTMAPK9MAPK10MEN1KMT2A | |
| SCHEMBL2421831 | 0.85 | MAPK9 (0.55) | MAPTMAPK9MAPK10MEN1KMT2A | |
| SCHEMBL7896125 | 0.84 | MAPK9 (0.53) | MAPTMAPK9MAPK10MEN1KMT2A | |
| SCHEMBL2424312 | 0.84 | MAPK9 (0.55) | MAPTMAPK9MAPK10MEN1KMT2A | |
| SCHEMBL3480052 | 0.83 | MAPK9 (0.51) | MAPTMAPK9MAPK10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | claimed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | claimed |
| EP-1218374-B1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-16 | — | — | EP | claimed |
| EP-1088821-A1 | Pharmaceutically active sulfonamide derivatives | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-04 | — | — | EP | claimed |
| US-8658640-B2 | JNK inhibitors for the treatment of endometriosis | MERCK SERONO SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8012995-B1 | Pharmaceutically active sulfonamide derivatives | MERCK SERONO SA (CH) | 2011-09-06 | — | — | US | disclosed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | LABORATOIRES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-02-14 | — | — | US | disclosed |
| EP-1850846-A1 | COMPOSITION COMPRISING A JNK INHIBITOR AND CYCLOSPORIN | Laboratoires Serono SA (CH) | 2007-11-07 | — | — | EP | disclosed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | disclosed |
| EP-1663193-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | Applied Research Systems ARS Holding N.V. (AN) | 2006-06-07 | — | — | EP | disclosed |
| EP-1218374-B1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005097116-A1 | COMPOSITION COMPRISING A JNK INHIBITOR AND CYCLOSPORIN | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005025558-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2005-03-24 | — | — | WO | disclosed |
| EP-1088821-A1 | Pharmaceutically active sulfonamide derivatives | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | MAPKAPK2, JUN, MAP3K13 | MAPT 530/4885MAPK9 33/4885MAPK10 35/4885 |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | CBR3, INSR, CS | MAPT 4862/4885MAPK9 2768/4885MAPK10 1940/4885 |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | LCK, MAPKAPK2, MAP3K20 | MAPT 466/4885MAPK9 36/4885MAPK10 40/4885 |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | MAPT 2887/4885MAPK9 49/4885MAPK10 40/4885 |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | MAPKAPK2, MAP3K20, MAP3K6 | MAPT 3007/4885MAPK9 35/4885MAPK10 26/4885 |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | MAPT 2887/4885MAPK9 49/4885MAPK10 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.